Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Mier

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Lymphokine Research|January 1, 1982
Fever, interleukin-1 and host defense against malignancyC A Dinarello, R A Dempsey, J W Mier, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1987
Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cellsJ W Mier, C A Dinarello, M B Atkins, et al.
Journal of Biological Response Modifiers|February 1, 1985
Dissimilarities between purified human interleukin-1 and recombinant human interleukin-2 in the induction of fever, brain prostaglandin, and acute-phase protein synthesisJ W Mier, L M Souza, M Allegretta, et al.
Blood|November 15, 1991
Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytesG Vachino, J A Gelfand, M B Atkins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1996
Protease-resistant L-selectin mutants. Down-modulation by cross-linking but not cellular activationJ H Stoddart, R R Jasuja, M A Sikorski, et al.
Cytokine|March 1, 1994
Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humansH Tilg, E Trehu, L Shapiro, et al.
European Cytokine Network|April 22, 1999
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapyE Vannier, A Kaser, M B Atkins, et al.
Journal of Immunological Methods|August 9, 1993
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapyH Tilg, D Pape, E Trehu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1991
Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot studyP A Demchak, J W Mier, N J Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical responseJ A Gollob, J W Mier, K Veenstra, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Lymphokine Research|January 1, 1982
Fever, interleukin-1 and host defense against malignancyC A Dinarello, R A Dempsey, J W Mier, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1987
Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cellsJ W Mier, C A Dinarello, M B Atkins, et al.
Journal of Biological Response Modifiers|February 1, 1985
Dissimilarities between purified human interleukin-1 and recombinant human interleukin-2 in the induction of fever, brain prostaglandin, and acute-phase protein synthesisJ W Mier, L M Souza, M Allegretta, et al.
Blood|November 15, 1991
Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytesG Vachino, J A Gelfand, M B Atkins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1996
Protease-resistant L-selectin mutants. Down-modulation by cross-linking but not cellular activationJ H Stoddart, R R Jasuja, M A Sikorski, et al.
Cytokine|March 1, 1994
Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humansH Tilg, E Trehu, L Shapiro, et al.
European Cytokine Network|April 22, 1999
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapyE Vannier, A Kaser, M B Atkins, et al.
Journal of Immunological Methods|August 9, 1993
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapyH Tilg, D Pape, E Trehu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1991
Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot studyP A Demchak, J W Mier, N J Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical responseJ A Gollob, J W Mier, K Veenstra, et al.
Pageof 9